ANNXHealthcare · BiotechnologyThe 10 Wall Street analysts covering Annexon, Inc. hold a median 12-month price target of $15 — +270.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Annexon, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (65): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (21): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ANNX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +270.4% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $14 → $25 |
| 30 Sept 2026 | JP Morgan | Maintains | Overweight | $14 → $15 |
| 30 Sept 2026 | JP Morgan | Maintains | Overweight | — |
| 1 Sept 2026 | JP Morgan | Maintains | Overweight | — |
| 1 Sept 2026 | JP Morgan | Maintains | Overweight | $10 → $14 |
| 13 Aug 2026 | Citizens | Upgrade | Market Perform | — |
| 13 Aug 2026 | Citizens | Upgrade | Market Perform | — |
| 21 July 2026 | Citizens | Initiates | Market Underperform | $3.00 |
| 21 July 2026 | Citizens | Initiates | Market Underperform | — |
| 15 July 2026 | Needham | Maintains | Buy | $11 → $25 |
| 15 July 2026 | Needham | Maintains | Buy | — |
| 12 May 2026 | Goldman Sachs | Initiates | Neutral | — |
| 20 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 23 Dec 2025 | Chardan Capital | Initiates | Buy | — |
| 2 Dec 2025 | Clear Street | Initiates | Buy | — |
| 19 Nov 2025 | Wells Fargo | Maintains | Overweight | — |
| 15 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 May 2025 | Needham | Maintains | Buy | — |
| 4 Mar 2025 | Needham | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ANNX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Annexon, Inc. returned +38.2% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 24% of US stocks
Cheaper than 76% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 13% of US stocks
Higher than 7% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Annexon, Inc. has a market value of $767.8M and an enterprise value of $583.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$202.7M.
Diluted earnings per share, trailing twelve months: $−1.16.
Free cash flow in the twelve months to 30 June 2026: −$193.2M.
Trailing P/E: −3.0×; forward P/E: −3.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Annexon, Inc. employs 92 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Annexon, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Annexon announced a virtual investor event for November 3, 2026, at 11:00 a.m. ET, regarding its Phase 3 ARCHER II program for vonaprument in geographic atrophy.
Why it matters — The event will provide ANNX watchers an opportunity to hear about key aspects of the ARCHER II Phase 3 program.
Annexon announced inducement grants to six new non-executive employees under its 2022 Employment Inducement Award Plan.
Why it matters — The grants are a compensation-related company update disclosed under Nasdaq Listing Rule 5635(c)(4).
Annexon is focusing on functional patient outcomes in geographic atrophy and Guillain-Barré syndrome, aiming for clinical differentiation through preservation of vision and physical recovery. The company maintains a cash runway into 2028 supported by $209.2M in liquidity and a $200M Oxford Finance facility, with ARCHER II trial readouts expected in Q4 2026.
Why it matters — A watcher would care because the ARCHER II trial's shift to functional vision endpoints and the 2026 readouts could determine whether Annexon achieves clinical differentiation and market expansion in geographic atrophy.
Annexon announced two oral presentations on vonaprument at The Retina Society 59th Annual Scientific Meeting, covering patient baseline characteristics from the Phase 3 ARCHER II pivotal trial for geographic atrophy as well as Phase 2 vision protection data. The company noted month 15 results from ARChER II are expected in the fourth quarter of 2026.
Why it matters — A watcher of ANNX would care because these presentations highlight the positioning of the Phase 3 ARCHER II trial to potentially replicate Phase 2 vision outcomes, providing insight into the program's progress ahead of the anticipated 2026 readout.
Annexon announced that it granted equity inducement awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved on September 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
Why it matters — This news is relevant to Annexon watchers as it reflects the company's hiring and equity compensation activity, though it does not directly affect its pipeline or financial results.
The 10 Wall Street analysts covering Annexon, Inc. have a median 12-month price target of $15, with estimates ranging from $7 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Annexon, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Annexon, Inc. 39 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Annexon, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (65 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +270.4% from the last close, and Ticker Nerd's factor model ranks Annexon, Inc. 39 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Annexon, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $27 over the next 12 months.
Annexon, Inc. returned +38.2% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Annexon Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target classical complement-driven inflammation in diseases of the body, brain, and eye.
The most recent item we track (GlobeNewsWire, 28 Oct 2026): "Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial". Annexon announced a virtual investor event for November 3, 2026, at 11:00 a.m. ET, regarding its Phase 3 ARCHER II program for vonaprument in geographic atrophy.
Annexon Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target classical complement-driven inflammation in diseases of the body, brain, and eye. The company’s current pipeline includes investigational medicines for autoimmune, neurodegenerative, neuroimmune, and ophthalmic conditions, with programs designed to block C1q, the initiating molecule of the classical complement pathway. Its product candidates are being studied across areas such as Guillain-Barré syndrome, geographic atrophy, and other serious inflammatory disorders. Annexon’s work centers on complement biology, a mechanism involved in immune activation and tissue damage, giving the company a distinct position within precision immunotherapy research. Headquartered in Brisbane, California, Annexon serves the biotechnology and drug development market through clinical research, translational science, and late-stage therapeutic development.
CEO Mr. Douglas E. Love Esq., J.D. · 92 employees · United States · https://www.annexonbio.com
